Previous 10 | Next 10 |
home / stock / biovf / biovf news
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q3 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2020 Q3 - Results - Earnings Call Presentation
Sobi publishes report for the third quarter 2020 PR Newswire STOCKHOLM, Oct. 22, 2020 STOCKHOLM , Oct. 22, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2020. Total revenue for...
A Phase 3 clinical trial evaluating Swedish Orphan Biovitrum AB's (BIOVF) Doptelet (avatrombopag) in solid tumor patients with chemo-induced thrombocytopenia (low blood platelets) failed to achieve the primary endpoint.The 122-subject study did not meet the composite endpoint of avoiding plat...
Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia PR Newswire STOCKHOLM, Oct. 9, 2020 STOCKHOLM , Oct. 9, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today anno...
Invitation - Presentation of Sobi's Q3 2020 results PR Newswire STOCKHOLM, Oct. 7, 2020 STOCKHOLM , Oct. 7, 2020 /PRNewswire/ -- On 22 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quar...
After the company reported its gout drug, SEL-212, failed to meet its primary endpoint in a mid-stage clinical trial, shares in Selecta Biosciences (NASDAQ: SELB) traded 33.5% lower on Thursday. The biotech stock licensed SEL-212 -- a combination of Selecta's synthetic vacci...
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout - All data consistent with stronger performance of SEL-212 versus pegloticase - N...
Selecta Biosciences (SELB) and its collaborating partner Swedish Orphan Biovitrum (BIOVF) announced topline data from Phase 2 COMPARE trial comparing SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and therapeutic uricase enzyme (pegadricase), to Horizon Therapeuti...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Swedish Orphan Biovitrum's ( OTCPK:BIOVF ) for the treatment of adults with alkaptonuria , a rare inherited disorder caused by the accumulation of homogentisic acid in the body due to ...
The European Medicines Agency's advisory group CHMP has adopted a negative opinion against approval of Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in children under the age of 18. More news on...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clin...
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a pot...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...